The United Kingdom’s first NHS EndoBarrier service for long-standing poorly controlled type 2 diabetes and obesity: outcomes one year after EndoBarrier removal

Robert E J Ryder, Mahi Yadagiri, Wyn Burbridge, Susan P Irwin, Hardeep Gandhi, Tahira Bashir, Rachael A Allden, Melanie Wyres, Melissa Cull, John P Bleasdale, Edward N Fogden, Mark R Anderson, Piya Sen Gupta


Aims: EndoBarrier is a 60 cm duodenal–jejunal bypass liner endoscopically implanted for up to one year. It mimics the bypass part of Roux-en-Y bariatric surgery and reduces weight and HbA1c while it is in situ. We aimed to assess the extent to which these improvements are sustained in people with diabetes in the year following removal.

Methods: Between October 2014 and November 2017 we implanted 62 EndoBarriers in an NHS service with all removed by November 2018. Outcomes were monitored in a registry.

Results: By November 2019, 46/62 (72%) (mean±SD age 51.5±7.7 years, 52% male, 54.3% white ethnicity, median (IQR) diabetes duration 14.5 (8–20) years, 67.4% insulin-treated and mean±SD body mass index (BMI) 41.6±7.1 kg/m2) had attended and 16/62 (28%) did not attend their one-year post-EndoBarrier follow-up appointment. In those who attended, during EndoBarrier implantation mean±SD HbA1c fell by 21.1±19.6 mmol/mol from 77.1±20.0 to 56.0±11.2 mmol/mol (p<0.001) (by 1.9±1.8% from 9.2±1.8% to 7.3±1.0% (p<0.001)), weight fell by 17.2±8.8 kg from 121.9±29.4 kg to 104.7±30.1 kg (p<0.001), BMI fell from 41.6±7.5 to 35.5±7.5 kg/m2 (p<0.001), systolic blood pressure from 139.0±14.0 to 126.0±14.6 mmHg (p<0.001) and serum alanine aminotransferase from 30.0±16.9 to 18.8±11.0 U/L (p<0.001). Median (IQR) total daily insulin dose reduced from 104 (54–162) to 30 (0–62) units (n=31, p<0.001); 10/31 (32%) insulin-treated people with diabetes were able to discontinue insulin. One year post-EndoBarrier, 18/46 (39%) demonstrated fully sustained improvement, 18/46 (39%) partially sustained improvement and 10/46 (22%) reverted to baseline. Of those deteriorating, 9/10 (90%) had depression and/or bereavement; they also had less fall in weight and HbA1c during EndoBarrier treatment. In the 16/62 (28%) who did not attend follow-up, reasons for non-attendance were too far to travel (25%), need to take time off work (6.3%), severe depression (6.3%) and death (6.3%). In 56.3% of cases no reason was given.

Conclusion: Our data demonstrate that EndoBarrier is highly effective in people with long-standing poorly controlled type 2 diabetes and obesity, with maintenance of significant improvement one year after removal in 78% of cases for whom data were available. As an endoscopic procedure it is relatively simple and non-invasive and it deserves further investigation.


EndoBarrier, duodenal–jejunal bypass liner, DJBL, obesity, type 2 diabetes, diabesity, bariatric surgery

Full Text:



Instructions for Use - EndoBarrier GI Liner with Delivery System - GID part number 50-10-00552 Rev N. (accessed 12 March 2021).

Jirapinyo, Haas AV, Thompson CC. Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. Diabetes Care 2018;41(5):1106–15.

Laubner K, Riedel N, Fink K, et al. Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: a case control study. Diabetes Obes Metab 2018;20(8):1868–77.

de Jonge C, Rensen SS, Verdam FJ, et al. Endoscopic duodenal–jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg 2013;23:1354–60.

Betzel B, Homan J, Aarts EO, et al. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study, Surg Endosc 2017;31:2881–91.

Kaválková P, Mráz M, Trachta P, et al. Endocrine effects of duodenal–jejunal exclusion in obese patients with type 2 diabetes mellitus. J Endocrinol 2016;231(1):11–22.

Koehestanie P, Dogan K, Berends F, et al. Duodenal-jejunal bypass liner implantation provokes rapid weight loss and improved glycemic control, accompanied by elevated fasting ghrelin levels. Endosc Int Open 2014; 2(1):E21–E27.

Ryder REJ, Irwin SP, Burbridge W, et al. The United Kingdom's first NHS Endobarrier service for advanced diabesity: 1-year outcomes for all 62 treated patients. Br J Diabetes 2019;19:110–17.

Hayee B, Sen Gupta P, Anderson M, et al. Endoscopic proximal intestinal exclusion can improve non-alcoholic fatty liver disease (NAFLD) in patients with diabesity. Proceedings of the Digestive Diseases Week (DDW), San Diego, May 2016.

The UKPDS Risk Engine v2.0. (accessed 18 February 2021).

NHS England. Friends and Family Test. (accessed 18 February 2021).

GI Dynamics. GI Dynamics receives CE Certificate of Conformity withdrawal notice for EndoBarrier. (accessed 18 February 2021).

EndoBarrier System Pivotal Trial ( Rev B) (STEP-1). (accessed 12 March 2021).

Betzel B, Koehestanie P, Homan J, et al. Changes in glycemic control and body weight after explantation of the duodenal-jejunal bypass liner. Gastrointest Endosc 2017;85(2):409–15.

Vilarrasa N, Ruiz de Gordejuela AG, Casajoana A, et al. Endobarrier® in grade i obese patients with long-standing type 2 diabetes: role of gastrointestinal hormones in glucose metabolism. Obes Surg 2017;27(3):569–77.

International Diabetes Federation. Worldwide toll of diabetes. IDF Diabetes Atlas. 9th Edition, 2019. (accessed 18 February 2021).

Birmingham EndoBarrier Treated Patients. Pictures obtained with written consent for online publication. (accessed 18 February 2021).

Interviews with Birmingham EndoBarrier Treated Patients. Video footage obtained with written consent for online publication. (accessed 18 February 2021).

GI Dynamics Announces Selection of New Notified Body. (accessed 18 February 2021).



  • There are currently no refbacks.

The Journal of the Association of British Clinical Diabetologists